Kardigan, Inc. is a biopharmaceutical company developing treatments for cardiovascular conditions, particularly cardiomyopathies and heart failure. The company employs a proprietary platform that combines artificial intelligence tools, clinical data from real-world settings, and cardiac-specific analytical methods to inform drug design and clinical trials, leveraging FDA-approved algorithms and extensive patient information from its Prolaio platform. It pursues strategic partnerships and acquisitions to build out its therapeutic pipeline for the cardiology market.

entry readiness 51 · MODERATE · exit proximity 0

Value area 12.23–21.09 · 83% of 103d volume overhead · heavy supply